LRMR Larimar Therapeutics Inc Total Asset Value of Company

The biopharmaceutical business of Larimar Therapeutics (LRMR) relies on demand within the rare brain pathology niche, yet faces raw material logistics threats and patent disputes. This chart of total assets, valued at 157.64, highlights the lack of stable income due to the product development stage. High price volatility is driven by the potential failure of ataxia drug trials and a liquidity deficit pending the FDA verdict.

LRMR (Larimar Therapeutics) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Larimar Pharma (LRMR)

- stock price and consensus target price:

Price Performance Chart larimartx.com|LRMR - Price Target Chart

- market capitalization data:

Market Valuation Larimar Corp|LRMR - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Larimar Therapeutics|LRMR - Book Capitalization|Market Capitalization to Book Value Ratio larimartx.com|LRMR - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Larimar Therapeutics|LRMR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Larimar Corp|LRMR - Company Aggregate Debts|Debts to Book Capitalization Larimar Corp|LRMR - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Larimar Therapeutics|Immediate Liquidity Ratio larimartx.com

- net income and valuation multiples indicators:

LRMR - Net Profit

Fundamental valuation:Larimar Therapeutics

Manufactured products of Larimar Therapeutics

For Larimar Therapeutics (LRMR), the total assets chart reflects the material base, including specialized logistics for rare neurological pathology drugs. This indicator consolidates the aggregate value of all company resources, combining equity and external liabilities. The value is calculated inversely via return on assets (ROA), allowing for an assessment of the scale of operational control. An upward trend signals expanding business potential, although excessive debt load may heighten financial risks.

Key competitors

jazzpharma.com - Aggregate Asset Value|Aggregate Company Assets Cytokinetics, Incorporated|PTC Therapeutics Inc - Total Asset Value of Company|Company Total Assets SRRK|CNTA (Centessa Corp) - Aggregate Asset Value|Company Total Assets DYN (Dyne Therapeutics, Inc.)|Company Total Assets edgewisetx.com EWTX|RAPP - Aggregate Company Assets|Aggregate Asset Value ALMS (Alumis Inc)|Kempharm (ZVRA) - Aggregate Company Assets|Cumulative Company Assets Contineum Corp|CAPR (Capricor Therapeutics Inc.) - Company Total Assets|Company Total Assets entradatx.com|Cumulative Company Assets PTHS (Channel Therapeutics Corp)|MNOV (medicinova.com) - Aggregate Asset Value|Aggregate Company Assets Serina SER|BTAI: Total Business Assets|ProMIS - Company Total Assets|Company Assets Apimeds Pharmaceuticals|AEON (aeonbiopharma.com) - Cumulative Company Assets|NLS Pharmaceutics (NLSP) - Company Total Assets|Aggregate Company Assets Bionomics Ltd.|HUGE: Aggregate Asset Value|Aggregate Company Assets Reata Pharmaceuticals (RETA)